Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 291Carcinoma, Non-Small-Cell Lung 222Neoplasms 193Prostatic Neoplasms 158Multiple Myeloma 138Neoplasm Metastasis 115Melanoma 110Colorectal Neoplasms 107Leukemia, Myeloid, Acute 103Lymphoma 97Lung Neoplasms 94Ovarian Neoplasms 84Squamous Cell Carcinoma of Head and Neck 75Lymphoma, Non-Hodgkin 73Leukemia, Lymphocytic, Chronic, B-Cell 70Pancreatic Neoplasms 64Triple Negative Breast Neoplasms 62Myelodysplastic Syndromes 62Parkinson Disease 4, Autosomal Dominant Lewy Body 59Hematologic Neoplasms 59Head and Neck Neoplasms 59Recurrence 56Glioblastoma 55Leukemia 53Precursor Cell Lymphoblastic Leukemia-Lymphoma 52Sarcoma 49Brain Neoplasms 49Lymphoma, Large B-Cell, Diffuse 47Carcinoma, Hepatocellular 47Lymphoma, Follicular 45

Interventions

Sirolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Exanthema × 1 year × Clear all
NCT03363763 2025-12-01

Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex

Aucta Pharmaceuticals, Inc

Phase 2 Terminated
24 enrolled 11 charts

Erythema, Exanthema, Fibroma, Tuberous Sclerosis, Facies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡